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Abstract 
A549 xenografts were allowed to grow in nude mice to about 5 mm in diameter, then diets were changed to modified AIN-76 
diets containing 19% wt/wt. fish oil (FO) or 20% wt./wt. com oil (CO). Ten days later dietary ferric citrate (0.3% wt./dry wt.) 
was added and doxoribicin (DOX) treatment (3.6 mg/kg i.v. each of the 5 days for 18 days) commenced. Treatment with DOX 
halted the growth of tumors in the CO fed mice. However, in those mice, which consumed FO or FO with ferric citrate, 
treatment with DOX caused significant tumor regression. © 2000 Elsevier Science Ireland Ltd. All rights reserved. 
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1. Introduction 
Doxrubicin (OOX) is commonly used as a compo-
nent of the chemotherapy regimen for the treatment of 
a wide variety of human cancers including adenocar-
cinomas, sarcomas, melanomas, leukemias, and 
lymphomas [13]. We and others [9,14,15,25,26] 
have proposed that use of polyunsaturated fatty 
acids (PUPAs) prior to chemotherapy, may sensitize 
cancers to the effects of a chemotherapeutic drug. In 
vitro studies indicate that addition of PUFA from fish 
oil, including eicosapentanoic and docasahexanoic 
acids, to the culture media, did increase the efficacy 
of the chemotherapeutic drug against different cancer 
cell types including: ZR-75-1 breast [5,6], trans-
*Corresponding author. Tel.: + 1-210-567-3896; fax: + 1-210-
567-3803. 
E-mail address: hardrnan@uthscsa.edu (W.E. Hardman) 
formed rat fibroblasts [1], L1210 leukemic cells 
[11], A549 lung, PC-3 prostate [5], THKE tumori-
genic human kidney epithelial [19], and MDA-MB 
231 breast cancer cells [14]. However, to date, in 
vivo studies on dietary PUFAs in addition to 
chemotherapy treatment have been limited to breast 
cancer cell types. We wanted to see if the concept of 
supplementation of the diet of xenograft bearing mice 
with the fatty acids of fish oil would increase the 
efficacy of treatment of other types of cancers. 
In the study described in this brief report, human 
A549 lung cancer cells were implanted subcuta-
neously (s.c.) on the backs of nude mice. The tumors 
were allowed to grow to about 5 mm in diameter, then 
the diet was changed to include 20% corn oil or 19% 
fish oiV1% corn oil. The mice were fed the high oil 
diets for ten days to allow substitution of the dietary 
fatty acids into cellular membranes before treatments 
were initiated. The treatment wao; DOX at 3.8 mglkg 
0304-3835/00/$ - see front matter © 2000 Elsevier Science Ireland Ltd. All rights reserved. 
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body weight i.v., once each five days with or without 
ferric citrate dietary supplementation. The extra iron 
was added to the diet with the idea that the iron would 
serve as a prooxidant to add to the prooxidation poten-
tial of DOX. It was found that there was significant 
tumor regression in the mice, which consumed fish oil 
diets before and during DOX treatment but not in the 
mice which consumed corn oil diets before and during 
DOX treatment. To our knowledge, this is the first 
report demonstrating that dietary fish oil can increase 
the efficacy of a chemotherapeutic drug against a 
human lung cancer xenograft. 
2. Methods and materials 
2.1. Tumor cells 
A549 human lung cancer cells (American Type 
Culture Collection, Rockville, MD) were cultured 
for injection in nude mice. The culture medium was 
an enriched Ll5:SMEM base media supplemented 
with other factors as described previously [21]. 
2.2. Animals 
Twenty-five male nude mice were allowed to accli-
mate for one week then were inoculated with tumor 
cells. The mice were housed under aseptic conditions 
(positive air pressure in a designated nude mouse 
room, cages, bedding, water and food were sterilized, 
cages had microisolator tops) in a temperature (24°C) 
and light controlled (12 h light per day) room. All 
mouse handling was carried out under a laminar 
flow hood. Our Institutional Animal Care and Use 
Committee approved all animal use and handling 
before commencing the experiment. The animal care 
facilities are accredited by the American Association 
for the Accreditation of Laboratory Animal Care. 
2.3. Experimental design 
Cultured A549 cells were harvested, rinsed and 
suspended in serum-free L15:SMEM culture medium. 
Cells in suspension were counted using a hemocyt-
ometer and the cell count was adjusted to 108/ml. 
The suspension was kept well mixed during the time 
of injection. A549 cells (5 X 106 cells in 0.05 ml of 
serum free media) were injected s.c. on the upper back 
of each mouse. 
The experimental design for the tumor bearing 
mice is diagrammed in Fig. 1, day 0 is the day of 
change to the high com oil or fish oil diets. Mice 
were fed a regular mouse chow diet while the tumors 
were allowed to grow to about 5-mm diameter. This 
allowed the tumors to become established as growing 
tumors in the host mice before onset of the experi-
mental diets. The tumor bearing mice were then 
divided into groups and placed on diets based on the 
AIN-76A diet but modified to contain either 20% com 
oil or 19% menhaden fish oil with 1% com oil. 
Compositions of the experimental diets are listed in 
Table I. One percent com oil was included in the fish 
oil diet to prevent the complications of essential fatty 
acid deficiency. Fifteen mice received the high com 
oil diet and 10 mice received the high fish oil diet. The 
mice were maintained on these diets for ten days to 
allow substitution of cellular membrane fatty acids 
before beginning treatment with DOX or DOX and 
ferric citrate. The diets were prepared weekly, indivi-
dual daily portions for each cage were packaged and 
the packages were stored in sealed containers at 
-20°C to suppress spontaneous lipid peroxidation. 
The food was replaced daily to prevent consumption 
of oxidized lipids. 
Treatment, defined as DOX alone or OOX with 
supplemental ferric citrate in the diet, was initiated 
after ten days on the corn oil or fish oil diets. Supple-
mental ferric citrate wa<; added to the diet of five mice 
on the fish oil diet and five mice on the corn oil diet, at 
a rate of 0.3% of the dry weight of the food. An 
untreated control group of five mice continued on 
the com oil diet. DOX was obtained as Adriamycin 
PFC (Pharmacia & Upjohn, Inc. Kalamazoo, MI) 






Phase I Phase II 
Day 14 
5 inlce, fish oil, DOX 
Fig. l. Diagram of the experimental design. 
Day ~8 
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Table 1 
Composition of the diet by weight percent (g/ 100 g of food) 
Com oil diet Fish oil diet 
Ingredient" 
Com oil 20.0 1.0 
Menhaden oil 19.0 
Sugar 27.9 27.9 
Casein 232 23.2 
Cornstarch 17.4 17.4 
AIN-76 vitamin mixb l.l5 1.15 
AIN-76 mineral mixb 4.06 4.06 
Choline bitartrate 0.23 0.23 
oL-methionine 0.35 0.35 
Cellulose 5.8 5.8 
Total 100.1 100.1 
Composition of the diets by % calorie.v" 
Protein 20.6 20.6 
Carbohydrated 40.1 40.1 
Fat 39.3 39.3 
Energy content of 4.52 4.52 
each diet (kcaJ/ g) 
• Diet components and chemicals- Purified high nitrogen casein, 
pure com starch, Alphacel (non-nutritive bulk cellulose) AIN-76 
vitamin mixture. AIN-76 mineral mixture and choline bitartrate 
(99% pure) was obtained from ICN Nutritional Biochemicals, 
Cleveland, OH. Imperial brand (Sugarland. TX.) extra fine pure 
cane sugar and I 00% pure com oil (Wesson) was purchased locally. 
oL-methionine (cell culture, M.W. 149.2), menhaden fish oil and 
ferric citrate was purchased from Sigma, St. Louis, Missouri. 
b a-Tocopherol is 0.02 g/100 g and ferric citrate (16-17% Fe3+) 
is 0.02 g/100 g of the ba.~aJ diet. 
• Caloric content is calculated at 4 kcal/g for protein and carbo-
hydrate and 9 kcal/g for fat. The diet which included a prooxidant 
(iron) had 0.3 g/100 g of ferric citrate (16-17% Fe3+) added to the 
19% MOor 20% CO diet. 
d The % of calories from carbohydrate include the calories from 
sucrose, cornstarch and sucrose in the vitamin and mineral mix. 
concentration of 2 mg/ml in the sterile isotonic solu-
tion. The DOX was stored under refrigeration and 
protected from light. A dose of 3.6 mg DOX/kg 
body weight (about 0.05 mV 28 g mouse) was injected 
into the lateral tail vein of the mice once each 5 days 
(days 10, 15, 20 and 25 after initiation of diet as in Fig. 
2). 
Tumor lengths and widths and body weights were 
measured three times weekly. Measurements were 
entered directly into an Excel spreadsheet. Tumor 
sizes were calculated using the formula for the volume 
of a prolate spheroid 
V = 4/3 X 3.14 XU2 X W/2 XD/2 
The width measurement was used as the depth of 
the tumor. This shape was a good approximation of 
the shape of the tumors. 
The experiment was terminated 18 days after the 
initiation of DOX treatment. The mice were anesthe-
tized using a ketamine/S.A. rompun mixture (0.2 cm3/ 
25 g weight, 1M) prepared by our Laboratory Animal 
Resources veterinarian, then killed by cervical dislo-
cation. Mice in the untreated group consuming com 
oil and the group consuming corn oil and treated with 
ferric citrate and DOX had to be killed early because 
of the large tumor size. 
2.4. Statistical analyses 
The growth of the tumors wa..<; divided into two 
phases: (1) phase I was defined as the 10 days during 
consumption of the com oil or fish oil diets plus four 
days for initiation of a response to the treatment, (2) 
phase II, the final 14 days, was defined as the time of 
response to the treatment. Regression analysis for 
Phase II was started at day 14 rather than day 10 
(the day of the first DOX injection), to allow time 
for response to DOX treatment to be reflected in a 
change in the tumor size. Linear regression analysis 
was used to determine if the change in the mean tumor 
size during Phase I or Phase II of the experiment 
showed a significant linear regression and to deter-
mine the slope (rate of growth of the tumor) of each 
linear regression. A significant positive slope indi-
cated tumor growth, a significant negative slope indi-
cated tumor regression and a non-significant slope 
Growth of A549 kJng cancer llllllOgrafls In nude mice 
;..DJglnnl~ 
-()-Com oN (no DOXtreatmanl) 
-+-Com ol and fentc citrate 
-l!t:- Flsh Clil 
...._ Fllh oil and ferric cllrale 
-Q-Corn ol 
5 10 15 20 25 30 
Days after lnitiallon of fish oil ciet 
Fig. 2. Effects of experimental diets and DOX on growth of A549 
lung cancer xenografts in nude mice (complete details under statis-
tical analyses in text (Section 2.4 ). 
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indicated no growth. Slope analysis for differences 
between the regression of the mean tumor volume 
for each group during the first or second phase of 
the study was performed by PRISM and INST AT soft-
ware (GraphPad Software, San Diego, CA) using the 
general linear model procedure to generate an 
ANOV A. The ANOV A indicated that differences 
were present, thus a Tuk:ey's multiple comparisons 
post test was conducted to determine differences 
between the slopes of each pair of lines against the 
null hypothesis that there was no difference between 
the slopes. A P s 0.05 was used to indicate that there 
was a significant difference between slopes of the 
regression lines and that the tumor growth rates repre-
sented by the slopes were significantly different. 
3. Results 
3.1. Body weight change 
Table 2 lists the mean change in body weight 
between day 0 (initiation of the experimental diets) 
and day 28 (termination) of the experiment for each 
dietary group. The results of ANOV A of the body 
weight indicate that there were no significant differ-
ences in the mean change in body weight due to the 
diet or treatment of the mice. At this dose of DOX and 
on these diets, all groups gained weight over the 
course of the experiment. This indicates that the 
mice tolerated the diets and treatments equally well. 
There was no indication of diarrhea or gastric distress 
in any of the mice. 
Table 2 
The mean change in body weights of the groups of mice from day 0 
(day of change to com oil or fish oil diets) to day 20 of the experi-
ment DOX was initiated on day 10 in all groups except the 'no 
DOXgroup' 
Final diet group (n = 5) 
Com oil 
Fish oil 
Corn oil+ Fe 
Fish oil+ Fe 
Com oil; no DOX 
Mean (g) ± so• 
+5.6:!: 2.0 
+4.8:!: 2.6 
+4.8 ± 1.6 
+4.2:!: 1.2 
+3.3:!: 0.7 
• ANOVA showed that there were no significant differences in 
the change in body weight due to the diet or treatment of the mice. 
3.2. Tumor growth 
Fig. 2 is a graph of the mean tumor size over the 
time of the experiment. Day 0 is the day that the diets 
of the mice were changed to the high com oil or high 
fish oil diets. The slope of the mean tumor size of each 
group was determined between day 0 and day 14 
(Phase I) and from day 14 to day 28 (Phase II). Slopes 
of the linear regression for each group and result<; of 
ANOVA are reported in Table 3. A summary of the 
results of ANOV A and Tukey' s multiple comparisons 
test of the tumor growth rates follows: 
( l) There was not a significant difference in the rate 
of growth of the tumor due to the diet composition 
during phase I of the experiment, regardless of 
whether the mice were consuming 20% corn oil 
or 19% fish oil plus 1% com oil in the diet. Thus, 
supplementation of the diet with fish oil did not 
significantly alter growth of this tumor prior to 
the treatment with DOX or DOX plus iron; 
(2) The type of oil in the diet, however, did make a 
significant difference in the efficacy of DOX treat-
ment. Specifically, DOX halted the growth of the 
tumors in the group of mice consuming com oil, 
Table 3 
Growth mte of A549 human lung tumors (mean mm3 per day + SD 
of slope) 
Final diet/treatment group Phase I" Phase II 
(n = 5) 
Com oil; DOX 14.8:!: 1.9 -1.5 ± 1.8h 
Fish oil; DOX 16.2 :!: 1.8 -11.1 :!: 1.5b 
Com oil + iron; DOX 15.9 ± 1.3 34.1 :!: 4.2b 
Fish oil + iron; DOX 11.2:!: 2.3 -13.1 ± 4.2b 
Com oil; no DOX 14.9:!: 2.0 14.9 ± 2.0h 
• Linear regression analyses showed that during phase I. all 
slopes were significantly different from 0. ANOVA of the slopes 
showed that the growth mtes of the tumors (slopes) were not signif-
icantly different from each other during Phase I, when mice were 
consuming either a com oil or a fish oil diet without added iron and 
without DOX treatment. 
b Linear regression analyses showed that the tumor growth rate(-
slope of the regression line) of the group of mice which consumed 
com oil and was treated with DOX was not significantly different 
from a slope of 0. The tumor growth rate of all other groups was a 
significant positive or negative slope. AN OVA followed by Tukey' s 
multiple comparisons test of the slopes showed that growth mtes 
(slopes) with the same letter are not significantly different, growth 
rates with different letters are significantly different. 
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that is, the slope of the regression line for the 
growth of these tumors was not significantly differ-
ent from zero (a horizontal line indicates no growth 
over the time of treatment). However, the tumors in 
the mice consuming fish oil and being treated with 
DOX significantly regressed, that is, the slope of 
the linear regression line for this group was signifi-
cantly negative; 
(3) The type of oil in the diet made a significant 
difference when the treatment was a combination of 
supplemental iron and DOX. In the mice fed com 
oil, the tumor continued to grow when the treatment 
was iron and DOX. However, in the mice fed fish 
oil, the tumors significantly regressed when the 
treatment was iron and DOX. 
4. Discussion 
In this brief report, we provide evidence that the 
efficacy of doxorubicin against A549 lung cancer 
xenografts was significantly increased when the 
AIN-76 diet formula (Table 1) was supplemented 
with fish oil and that there were no observed harmful 
side effects to the mice due to the consumption of fish 
oil. There was some unavoidable variation in the 
mean tumor size at the time of initiation of the diet. 
However, as shown in Table 3, the tumor growth rate 
of the group with the largest tumors (group 5) and of 
the group with the smallest tumors (group 1), both fed 
the com oil diet, were not significantly different indi-
cating that mean tumor size at the time of the diet 
change did not significantly alter the tumor growth 
rate. The effect of consumption of fish oil in the diet 
in the absence of DOX can be evaluated using the 
portion of the tumor growth curve analyzed prior to 
initiation of DOX treatment. There was no significant 
difference in growth rates between the groups which 
consumed com oil and those which consumed fish oil. 
Thus, neither fish oil alone nor the differences in 
tumor size at the time of diet change, significantly 
altered the growth rate of this tumor model prior to 
the initiation of DOX or DOX and iron treatment. 
The data show that, in mice fed com oil, DOX 
inhibited growth of, but did not cause regression of, 
the tumors. This indicates that the tumor cells were 
either growth arrested and/or that only a fraction of 
the tumor cell population was killed by the DOX. 
However, DOX did not inhibit growth of tumors of 
mice fed com oil with iron. A possible explanation for 
these results is that in the presence of dietary com oil, 
tumor cells that were not killed by OOX treatment had 
their growth stimulated by the iron in the diet. 
Unfortunately, we do not have adequate data to 
evaluate how the fish oil worked to suppress tumor 
growth. However, other reports do provide clues to 
how fish oil works to increase the efficacy of DOX 
chemotherapy. For example, increased lipid peroxida-
tion in the tumor is one likely mechanism for the 
increased efficacy of DOX following consumption 
of fish oil. One mechanism of action for DOX is the 
formation of DOX-metal complexes and the produc-
tion of free radical complexes [13]. The results of a 
number of reports show that membrane fatty acids of 
normal tissues [7,18,23,24,26] and of tumors [7], 
become more unsaturated when the mice consume 
fatty acids from fish oil instead of com oil. Providing 
the PUFA substrate in the cell membranes would be 
expected to increase the generation of free radicals 
and would be expected to increase the oxidative 
damage from these free radicals. In fact, the increased 
unsaturation of membrane lipids was associated with 
increased lipid peroxidation and decreased tumor 
growth in MDA-MB 231 xenografts treated with edel-
fosine (Hardman et al., unpublished results) or in MX-
1 xenografts treated with DOX compared to mice fed 
com oil [26]. 
Other mechanisms have also been proposed to 
account for the suppression of cancer growth by fish 
oil or combinations of fish oil and a drug. These 
mechanisms include: 
( 1) Decreased levels of PGE2 following dietary fish 
oil [16,28]. Decreased PG~ is associated with 
increased immune activity [17] and decreased 
tumor promotion and growth [12]~ 
(2) Decreased activity of protein kinase C (PKC), 
which has been associated with reversal of drug 
resistance [ 1 OJ and slowed angiogenesis (reviewed 
in [20]). 
In addition, the n-3 fatty acids offish oil have been 
shown to be beneficial to the patient by suppressing 
cancer cachexia [3,4,22,27] and by improving the 
response to radiotherapy [ 10]. Bougnoux et al. has 
reported that an increased amount of n-3 fatty acids 
in the composition of adipose tissue was associated 
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with better response to chemotherapy in brea~t cancer 
patients [8]. Atkinson et al. has reported that dietary 
docosahexanoic acid (22:6n-3) slowed tumor growth 
and enhanced bone marrow cellularity of mice 
injected with fibrosarcoma cells [2]. Use of the n-3 
fatty acids derived from fish oil as an adjuvant to 
therapy has the potential to increase the efficacy of 
the chemo- or X-radiation therapies in current use. 
Our future studies will be designed to provide 
adequate tumor tissue at sacrifice time to investigate 
the mechanisms of n-3 fatty acids to increase the effi-
cacy of cancer therapy. This information about the 
mechanisms of action of n-3 fatty acids will allow 
us to devise even more effective cancer treatment 
strategies. 
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